Dr. Martens plc Logo

Dr. Martens plc

DOCS.L

(1.8)
Stock Price

58,10 GBp

10.14% ROA

18.91% ROE

7.82x PER

Market Cap.

534.281.054,00 GBp

90.52% DER

4.59% Yield

7.89% NPM

Dr. Martens plc Stock Analysis

Dr. Martens plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Dr. Martens plc Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (48.48%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 Revenue Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 Dividend Growth

The company's dividend growth has shown a positive trajectory over the past three years, consistently increasing year after year, indicating a favorable trend for potential investors.

5 PBV

The stock's elevated P/BV ratio (3.48x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 DER

The stock is burdened with a heavy load of debt (120%), making it financially unstable and potentially risky for investors.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (24) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Dr. Martens plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Dr. Martens plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Dr. Martens plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Dr. Martens plc Revenue
Year Revenue Growth
2013 163.904.000
2014 235.300.000 30.34%
2015 232.400.000 -1.25%
2016 290.600.000 20.03%
2017 348.600.000 16.64%
2018 454.400.000 23.28%
2019 672.200.000 32.4%
2020 773.000.000 13.04%
2021 908.300.000 14.9%
2022 1.000.300.000 9.2%
2023 1.925.200.000 48.04%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Dr. Martens plc Research and Development Expenses
Year Research and Development Expenses Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Dr. Martens plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 0
2014 39.600.000 100%
2015 45.000.000 12%
2016 61.100.000 26.35%
2017 145.800.000 58.09%
2018 192.600.000 24.3%
2019 259.000.000 25.64%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Dr. Martens plc EBITDA
Year EBITDA Growth
2013 18.588.000
2014 38.400.000 51.59%
2015 29.200.000 -31.51%
2016 36.700.000 20.44%
2017 46.000.000 20.22%
2018 77.800.000 40.87%
2019 183.500.000 57.6%
2020 230.500.000 20.39%
2021 269.400.000 14.44%
2022 245.000.000 -9.96%
2023 355.600.000 31.1%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Dr. Martens plc Gross Profit
Year Gross Profit Growth
2013 75.904.000
2014 108.700.000 30.17%
2015 112.500.000 3.38%
2016 148.700.000 24.34%
2017 186.000.000 20.05%
2018 260.600.000 28.63%
2019 372.600.000 30.06%
2020 436.700.000 14.68%
2021 542.100.000 19.44%
2022 563.900.000 3.87%
2023 1.281.200.000 55.99%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Dr. Martens plc Net Profit
Year Net Profit Growth
2013 -32.000.000
2014 200.000 16100%
2015 -12.000.000 101.67%
2016 -11.300.000 -6.19%
2017 -5.700.000 -98.25%
2018 17.200.000 133.14%
2019 74.800.000 77.01%
2020 34.700.000 -115.56%
2021 181.200.000 80.85%
2022 128.900.000 -40.57%
2023 200.800.000 35.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Dr. Martens plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Dr. Martens plc Free Cashflow
Year Free Cashflow Growth
2013 -3.031.999
2014 17.800.000 117.03%
2015 21.500.000 17.21%
2016 27.700.000 22.38%
2017 29.600.000 6.42%
2018 38.900.000 23.91%
2019 94.100.000 58.66%
2020 128.800.000 26.94%
2021 148.600.000 13.32%
2022 20.300.000 -632.02%
2023 185.000.000 89.03%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Dr. Martens plc Operating Cashflow
Year Operating Cashflow Growth
2013 5.024.000
2014 19.800.000 74.63%
2015 25.800.000 23.26%
2016 34.400.000 25%
2017 46.000.000 25.22%
2018 56.000.000 17.86%
2019 116.000.000 51.72%
2020 146.100.000 20.6%
2021 173.600.000 15.84%
2022 71.700.000 -142.12%
2023 191.400.000 62.54%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Dr. Martens plc Capital Expenditure
Year Capital Expenditure Growth
2013 8.055.999
2014 2.000.000 -302.8%
2015 4.300.000 53.49%
2016 6.700.000 35.82%
2017 16.400.000 59.15%
2018 17.100.000 4.09%
2019 21.900.000 21.92%
2020 17.300.000 -26.59%
2021 25.000.000 30.8%
2022 51.400.000 51.36%
2023 6.400.000 -703.13%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Dr. Martens plc Equity
Year Equity Growth
2013 1.509.000
2014 800.000 -88.63%
2015 -11.000.000 107.27%
2016 -18.000.000 38.89%
2017 -29.400.000 38.78%
2018 -8.400.000 -250%
2019 70.500.000 111.91%
2020 149.700.000 52.91%
2021 328.200.000 54.39%
2022 404.200.000 18.8%
2023 368.200.000 -9.78%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Dr. Martens plc Assets
Year Assets Growth
2013 341.150.000
2014 363.200.000 6.07%
2015 376.000.000 3.4%
2016 420.200.000 10.52%
2017 445.800.000 5.74%
2018 450.200.000 0.98%
2019 656.500.000 31.42%
2020 651.800.000 -0.72%
2021 859.100.000 24.13%
2022 992.600.000 13.45%
2023 952.400.000 -4.22%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Dr. Martens plc Liabilities
Year Liabilities Growth
2013 339.641.000
2014 362.400.000 6.28%
2015 387.000.000 6.36%
2016 438.200.000 11.68%
2017 475.200.000 7.79%
2018 458.600.000 -3.62%
2019 586.000.000 21.74%
2020 502.100.000 -16.71%
2021 530.900.000 5.42%
2022 588.400.000 9.77%
2023 584.200.000 -0.72%

Dr. Martens plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.9
Net Income per Share
0.07
Price to Earning Ratio
7.82x
Price To Sales Ratio
0.61x
POCF Ratio
3.37
PFCF Ratio
3.87
Price to Book Ratio
1.47
EV to Sales
1.02
EV Over EBITDA
5.36
EV to Operating CashFlow
5.55
EV to FreeCashFlow
6.47
Earnings Yield
0.13
FreeCashFlow Yield
0.26
Market Cap
0,53 Bil.
Enterprise Value
0,89 Bil.
Graham Number
0.78
Graham NetNet
-0.31

Income Statement Metrics

Net Income per Share
0.07
Income Quality
2.32
ROE
0.19
Return On Assets
0.07
Return On Capital Employed
0.16
Net Income per EBT
0.74
EBT Per Ebit
0.74
Ebit per Revenue
0.14
Effective Tax Rate
0.26

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.61
Operating Profit Margin
0.14
Pretax Profit Margin
0.11
Net Profit Margin
0.08

Dividends

Dividend Yield
0.05
Dividend Yield %
4.59
Payout Ratio
0.84
Dividend Per Share
0.03

Operating Metrics

Operating Cashflow per Share
0.16
Free CashFlow per Share
0.14
Capex to Operating CashFlow
0.14
Capex to Revenue
0.03
Capex to Depreciation
0.34
Return on Invested Capital
0.13
Return on Tangible Assets
0.1
Days Sales Outstanding
26.3
Days Payables Outstanding
99.04
Days of Inventory on Hand
273.48
Receivables Turnover
13.88
Payables Turnover
3.69
Inventory Turnover
1.33
Capex per Share
0.02

Balance Sheet

Cash per Share
0,11
Book Value per Share
0,38
Tangible Book Value per Share
0.1
Shareholders Equity per Share
0.38
Interest Debt per Share
0.38
Debt to Equity
0.91
Debt to Assets
0.35
Net Debt to EBITDA
2.15
Current Ratio
2.85
Tangible Asset Value
0,10 Bil.
Net Current Asset Value
-0,15 Bil.
Invested Capital
786600000
Working Capital
0,28 Bil.
Intangibles to Total Assets
0.28
Average Receivables
0,10 Bil.
Average Payables
0,11 Bil.
Average Inventory
284550000
Debt to Market Cap
0.62

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Dr. Martens plc Dividends
Year Dividends Growth
2022 6
2023 6 0%
2024 3 -150%

Dr. Martens plc Profile

About Dr. Martens plc

Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.

CEO
Mr. Kenneth Wilson
Employee
2.630
Address
28 Jamestown Road
London, NW1 7BY

Dr. Martens plc Executives & BODs

Dr. Martens plc Executives & BODs
# Name Age
1 Ms. Emily Clare Reichwald
Chief Sustainability Officer
70
2 Mr. Sean O'Neill
Chief Digital Officer
70
3 Mr. Adam M. Meek
Chief Product Officer
70
4 Mr. Kenneth Wilson
Chief Executive Officer & Director
70
5 Graham Calder
Chief Technology Officer
70
6 Mr. Geert Peeters
Chief Operating Officer
70
7 Ms. Bridget Jolliffe
Chief People Officer
70
8 Mr. Giles Wilson
Chief Financial Officer & Director
70
9 Mr. Onyeije Ogueri Nwokorie
Chief Brand Officer
70
10 Mr. Derek Chan
President of APAC
70

Dr. Martens plc Competitors

Moonpig Group PLC Logo
Moonpig Group PLC

MOON.L

(1.8)
Darktrace plc Logo
Darktrace plc

DARK.L

(1.5)
THG Plc Logo
THG Plc

THG.L

(1.2)
Pets at Home Group Plc Logo
Pets at Home Group Plc

PETS.L

(2.0)